Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
TPGS TPG Pace Solutions Corp
SP SP Plus Corp
RDW Redwire Corp
BCAUY Brilliance China Automotive Holdings Ltd
RBC Regal Beloit Corp
WTRG Essential Utilities Inc
GRX Gabelli Healthcare & WellnessRx Trust
MILEW Metromile Inc *W EXP 02/09/2026
BRP BRP Group Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.

Price
Delayed
$71.46
Day's Change
-0.2312 (-0.32%)
Bid
--
Ask
--
B/A Size
--
Day's High
71.87
Day's Low
71.36
Volume
(Light)

Today's volume of 1,363,816 shares is on pace to be much lighter than GILD's 10-day average volume of 7,285,867 shares.

1,363,816

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.

Valuation Ratios

Price/Earnings (TTM)
17.52x
Price/Sales (TTM)
3.36x
Price/Book (MRQ)
4.54x
Price/Cash Flow (TTM)
12.73x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend

Short Interest

August 2021
Current Month
22.5M
Previous Month
25.7M
Percent of Float
1.79%
Days to Cover
3.5787 Days

Share Information

GILD is in a share class of common stock
Float
1.3B
Shares Outstanding
1.3B
Institutions Holding Shares
2,096
78.82%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Daniel O'DayChmn.
  • Andrew D. DickinsonCFO
  • Brett Alan PletcherExec.VP
  • Flavius MartinExec.VP
  • Johanna MercierOther

Address

Insider Trading

During the most recent quarter, 53K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.